Skip to main content
TeamingIndex
Unclaimed profileSeeded from SAM.gov and USAspending public records

LECTENZ BIO, INC.

UEIJTGCK219C6F4CAGE4XHN3NAICS541714
  • SAM active
  • No verified credentials yet
  • CMMCNot on file
  • SPRSNone
  • FCLVisible to paid members
  • Small Business

Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works

36-mo obligations
$0
Awards on record
0
Contract vehicles
0
Verified credentials
0

Compliance posture: unverified (SAM.gov baseline only)

LECTENZ BIO, INC. has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0

Claim this profile

About LECTENZ BIO, INC.

LECTENZ BIO, INC. is a SAM.gov-registered entity based in ATHENS, GA 30602-1514. UEI JTGCK219C6F4; CAGE 4XHN3; primary NAICS 541714. Compliance posture not provided. Active SAM registration.
Headquarters
ATHENS, GA 30602-1514

Identifiers

UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.

  • UEIJTGCK219C6F4
  • CAGE4XHN3

Capabilities & differentiators

No capability narrative yet

The company has not published a capability narrative. Its SAM.gov registration, NAICS codes and award history are below.

Compliance posture

Every credential shows who vouches for it: verified by TeamingIndex, or self-attested by the contractor.

No compliance posture published yet

Compliance facts appear once the company claims this profile and publishes them.

Facility clearance

Facility clearance: visible to paid members

Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans

No federal prime awards on record

USAspending shows no prime awards for this UEI in the last 36 months. Subcontract work does not appear here.

No contract vehicles on file

This company has not listed GWAC, IDIQ, GSA Schedule or OTA consortium holdings.
Who LECTENZ BIO, INC. has actually worked with, from sub-awards that prime contractors report to the government. Use it to see which primes already trust this company.

No sub-award reports yet

Prime contractors report first-tier subcontracts of $30,000 or more. None name this company yet, which is common for companies that mostly win prime contracts or work below the reporting threshold.

Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.

Small Business Innovation Research and Technology Transfer awards: early-stage federal R&D money this company has won.

SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects

Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.

Awards on record
17 awards
Total awarded
$13,012,610
By phase
  • SBIR Phase I: 9
  • SBIR Phase II: 5
  • STTR Phase I: 2
  • STTR Phase II: 1
By agency
  • Department of Health and Human Services: 17
Active projects
0 projects
Projects whose contract end date is today or later.
Phase II ending within 12 months
0 projects
Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
By year
  • 2025: 1
  • 2024: 1
  • 2023: 2
  • 2020: 3
  • 2018: 2
  • 2017: 2
  • 2015: 1
  • 2013: 2
  • 2012: 1
  • 2011: 1
  • 2009: 1

Awards (most recent first)

  • Innovative glycan-specific reagents to accelerate the detection of disease biomarkers

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2025 · $313,827

    Jul 18, 2025 – Jul 17, 2026

    Solicitation PAR24-131 (2024) · Topic 300

  • Engineered Pan-Specific Reagents for N-Glycan Detection and Enrichment

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2024 · $2,018,187

    Sep 15, 2024 – Aug 31, 2026

    Solicitation PA22-176 (2022) · Topic 100

  • A new approach to monitoring glycosylation during glycoprotein production

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2023 · $2,007,527

    Sep 15, 2023 – Aug 31, 2025

    Solicitation PA22-176 (2022) · Topic 300

  • Engineered Pan-Specific Reagents for N-Glycan Detection and Enrichment

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2023 · $301,703

    Aug 1, 2023 – Jan 31, 2024

    Solicitation PA22-176 (2022) · Topic 100

  • Development of a suite of high-specificity fucose binding reagents

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $450,000

    Mar 1, 2020 – Feb 28, 2022

    Solicitation PA16-157 (2016) · Topic 300

  • Novel Reagents for Monitoring Sulfation Patterns in Heparin and Heparan Sulfate

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $447,791

    Mar 1, 2020 – Feb 28, 2022

    Solicitation PA16-157 (2016) · Topic 300

  • Pan-specific tools and reagents for the enrichment of sialo-glycans

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2020 · $1,518,350

    Mar 1, 2020 – Feb 28, 2023

    Solicitation PA20-272 (2018) · Topic OD

  • Pan-specific tools and reagents for the enrichment of sialo-glycans

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $224,934

    Sep 1, 2018 – Feb 29, 2020

    Solicitation PA15-052 (2015) · Topic 100

  • High-specificity affinity reagents for the detection of glycan sialylation

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2018 · $1,049,907

    Jan 15, 2018 – Dec 31, 2020

    Solicitation PA16-157 (2016) · Topic 300

  • A rapid method for monitoring in vitro glycoengineering

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $300,000

    Sep 19, 2017 – Aug 31, 2019

    Solicitation PA16-157 (2016) · Topic 300

  • Reagents specific for all N-glycans

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $504,888

    Aug 1, 2017 – Jul 31, 2020

    Solicitation PA19-029 (2017) · Topic 400

  • High-specificity affinity reagents for the detection of glycan sialylation

    STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2015 · $698,157

    Jan 15, 2015 – Jun 30, 2017

    Solicitation PA11-214 (2016) · Topic 300 · Research partner: UNIVERSITY OF GEORGIA

  • High-specificity affinity reagents for N-glycosylation site mapping and glycomics

    STTR Phase II · Department of Health and Human Services (National Institutes of Health) · 2013 · $1,728,189

    Sep 20, 2013 – Aug 31, 2016

    Solicitation PA11-214 (2015) · Topic 300 · Research partner: UNIVERSITY OF GEORGIA

  • SBIR PHASE II TOPIC 294: DEVELOPMENT OF RESEARCH REAGENTS SPECIFIC FOR O-GLCNAC (

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2013 · $999,970

    Solicitation year 2013 · Topic NCI · Research partner: Stub

  • In-process glycoprofiling during recombinant therapeutic glycoprotein production

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2012 · $99,968

    Solicitation PA09-113 (2012) · Topic NIGMS · Research partner: Stub

  • SBIR TOPIC 294 PHASE 1 - DEVELOPMENT OF GLYCOSYLATION - SPECIFIC RESEARCH

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2011 · $148,851

    Solicitation year 2011 · Topic NCI · Research partner: Stub

  • High-specificity affinity reagents for N-glycosylation site mapping and glycomics

    STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2009 · $200,361

    Solicitation PHS2009-2 (2009) · Research partner: UNIVERSITY OF GEORGIA (UGA)

Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026

Cloud services this company lists on the FedRAMP Marketplace, the government's record of cloud authorizations.

No FedRAMP Marketplace listing

No FedRAMP Marketplace listing is linked to this company. Cloud providers appear here automatically once FedRAMP lists their offering.

Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded

Checks a prime runs before teaming: SAM.gov exclusions (debarment and suspension) and the government's Consolidated Screening List for export and sanctions lists.

SAM.gov exclusions

Not yet checked against SAM.gov exclusions.

Search exclusions on SAM.gov (opens in a new tab)

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded

Consolidated Screening List

No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.

Hourly ceiling rates this company was awarded on GSA contracts, compared with the market for similar labor categories. Ceiling rates are the most an agency can be charged, not prices paid.

No GSA CALC+ rates on record

Companies with a GSA Multiple Award Schedule contract appear here after CALC+ publishes their awarded labor rates.

NAICS, PSC & socio-economic status

Industry codes and small-business programs reported in SAM.gov.

NAICS codes

  • 541714Research and Development in Biotechnology (except Nanobiotechnology)PrimarySmall business under this code’s size standard

SAM.gov reports this entity as small under 1 of 1 NAICS code. Size is determined per code (SBA size standards).

Product & service codes (PSC)

No PSC codes reported.

This company has not published teaming preferences.

SAM.gov teaming eligibility: Eligible to be proposed as a team member: active SAM.gov registration and no exclusion.

Business development contact

No BD contact published

Contact details appear once the company claims this profile.
Immediate parent and highest-level owner as reported in SAM.gov.

No parent entity reported in SAM.gov.

SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.

Data sources & provenance

Who stands behind each fact on this page, and how to correct it.
  • SAM.gov

    Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.

  • USAspending.gov

    Prime award history and obligations (FPDS), synced nightly.

  • The contractor

    Nothing yet: this profile has not been claimed by the company.

  • TeamingIndex verification

    Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.

Corrections

Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)

Machine-readable: capability.md schema.org JSON-LD embedded in this page.

Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.

Teaming

Ready to team with LECTENZ BIO, INC.?

Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.